Pre-market Hot Trades in US Stocks
Mainz Biomed NV is down 9.68% in pre-market trading. Based on recent news,
<ol>
<li>
On February 17, Mainz Biomed announced a $6 million private placement and released a strategic update. The company plans to focus on developing its pancreatic cancer screening business in the United States while evaluating options to sell its colorectal cancer screening assets and closing its German subsidiary. This news has led to increased uncertainty among investors regarding the company's future, resulting in a decline in stock price.
</li>
<li>
On February 17, David Lazar was appointed as the chairman of the board. Although this appointment may have a positive impact on corporate governance, the market reacted more strongly to the company's strategic adjustments, causing the stock price to continue to fall.
</li>
<li>
On February 17, the company further disclosed transaction details during discussions with multiple parties regarding the sale of its colorectal cancer assets. These discussions and potential asset divestitures have heightened market concerns about the company's future business direction, further depressing the stock price. The recent volatility in the biopharmaceutical industry requires investors to exercise caution.
</li>
</ol>
Neo-Concept is down 8.47% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Top Gainers in Pre-market US Stocks
Kebang Technology is up 61.11% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 17, Kebang Technology's stock price surged 61.11% in pre-market trading, with the market expressing strong confidence in its future growth potential. According to analysis from Benzinga, Kebang Technology performed strongly in market momentum, scoring 85.49, indicating robust market performance.
</li>
<li>
On February 17, signals from Benzinga Edge indicated that Kebang Technology's market momentum score was higher than the overall market, suggesting its performance outpaced other competitors. This signal has boosted investor confidence in the stock, driving the price up.
</li>
<li>
On February 17, positive market sentiment towards Kebang Technology propelled its stock price upward, with Benzinga Pro data showing a 61.11% increase in pre-market trading. This rise reflects investors' optimistic expectations for its future growth potential. Market momentum is strong, and investor confidence is increasing.
</li>
</ol>
Auddia is up 60.52% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 17, Auddia announced the signing of a definitive merger agreement with Thramann Holdings and will be restructured into McCarthy Finney Holdings, with the stock ticker changing to MCFN. This transaction has been unanimously approved by both boards and is expected to be completed in the second quarter of 2026. This news has significantly boosted Auddia's stock price.
</li>
<li>
On February 18, Auddia released relevant documents in the EDGAR system, indicating that the completion conditions for the merger transaction include shareholder approval and the effectiveness of the SEC registration statement, as well as Auddia maintaining at least $12 million in net cash
This information further enhances market confidence in the success of the merger.
</li>
<li>
On February 18, technical analysis showed that Auddia's Relative Strength Index (RSI) was 45.94, indicating that the stock is in an oversold condition. Despite an 88.90% decline in stock price over the past 12 months, recent positive news has driven a rebound in stock price. Merger activity in the technology sector has increased, and market volatility has intensified.
</li>
</ol>
Beneficient rose 45.29% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 17, Beneficient released its third-quarter financial report, showing a net income of $19.9 million and revenue of $18.7 million, primarily due to cost management, asset sales, and legal resolutions. This result restored the company's profitability, strengthened its balance sheet, reduced debt, and regained NASDAQ compliance, driving the stock price up. Source: Beneficient SEC 8-K Current Report.
</li>
<li>
On February 17, Beneficient announced leadership changes, regained NASDAQ compliance, and resolved legal issues. Although operating losses widened due to asset sales and declines in net asset value, adjusted expenses decreased by 18% year-over-year. Management expects improved transaction flow and ongoing cost reductions, which have boosted market confidence. Source: Beneficient Q3 2026 Audio Transcript.
</li>
<li>
On February 17, Beneficient is set to release its quarterly financial report, with analysts predicting an earnings per share of -$0.15. Investors are looking forward to exceeding expectations and providing positive guidance for the next quarter. Last quarter's earnings per share fell short of expectations, leading to increased market attention on this quarter. Source: Benzinga. The market reacted positively to the financial report and compliance
</li>
</ol>

MYNZ

QUCY

Mainz Biomed NV pre-market down 9.68%; Neo-Concept pre-market down 8.47%; Kebaike Technology pre-market up 61.11%; Auddia pre-market up 60.52%; Beneficient pre-market up 45.29%

Pre-market hot trades in US stocks: Mainz Biomed NV pre-market down 9.68%; Neo-Concept pre-market down 8.47%